Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer's Disease

Stock Information for null

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About null

Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting
Alpha Cognition Announces Appointment of VP Finance and Accounting
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer's Disease
Alpha Cognition Announces Change of Officer
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
Alpha Cognition's Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
Alpha Cognition Announces First Quarter of 2024 Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.